Keloid disease can be inhibited by antagonizing excessive mTOR signaling with a novel dual TORC1/2 inhibitor

American Journal of Pathology

Volumn 181, Issue 5, 2012, Pages 1642-1658

  Syed, Farhatullah ^a   Sherris, David ^b   Paus, Ralf ^a,c   Varmeh, Shohreh ^d   Pandolfi, Pier P ^d   Bayat, Ardeshir ^a,e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Paloma Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF LÜBECK   (Germany)

^d HARVARD MEDICAL SCHOOL   (United States)

^e WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; CYCLIN D; CYCLINE; FIBRONECTIN; GLYCOGEN SYNTHASE KINASE 3BETA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PALOMID 529; PROTEIN KINASE B; PROTEIN S6; RAPAMYCIN; SERINE; UNCLASSIFIED DRUG; WORTMANNIN;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL ATTACHEMENT; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SPREADING; CELLULAR PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; KELOID; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; AGED; ANIMALS; APOPTOSIS; BENZOPYRANS; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBROBLASTS; HUMANS; KELOID; MALE; MIDDLE AGED; MULTIPROTEIN COMPLEXES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RATS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84868116581     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.08.006     Document Type: Article

References (81)

1. R. Watanabe, L. Wei, J. Huang mTOR signaling function, novel inhibitors, and therapeutic targets J Nucl Med 52 2011 497 500
2. C. Garcia-Echeverria Blocking the mTOR pathway: a drug discovery perspective Biochem Soc Trans 39 2011 451 455
3. A. Fasolo, C. Sessa Current and future directions in mammalian target of rapamycin inhibitors development Exp Opin Invest Drugs 20 2011 381 394
4. J.H. Ahn, S.K. Ahn, M. Lee The role of autophagy in cytotoxicity induced by new oncogenic B-Raf inhibitor UI-152 in v-Ha-ras transformed fibroblasts Biochem Biophys Res Commun 417 2011 857 863
5. D.A. Guertin, D.M. Sabatini Defining the role of mTOR in cancer Cancer Cell 12 2007 9 22 (Pubitemid 47001784)
6. P. Sini, D. James, C. Chresta, S. Guichard Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells Autophagy 6 2010 553 554
7. Q. Liu, C. Thoreen, J. Wang, D. Sabatini, N.S. Gray mTOR mediated anti-cancer drug discovery Drug Discov Today Ther Strateg 6 2009 47 55
8. E. Dazert, M.N. Hall mTOR signaling in disease Curr Opin Cell Biol 23 2011 744 755
9. A.S. Strimpakos, E.M. Karapanagiotou, M.W. Saif, K.N. Syrigos The role of mTOR in the management of solid tumors: an overview Cancer Treatment Rev 35 2009 148 159
10. M. Nakashima, S. Chung, A. Takahashi, N. Kamatani, T. Kawaguchi, T. Tsunoda, N. Hosono, M. Kubo, Y. Nakamura, H. Zembutsu A genome-wide association study identifies four susceptibility loci for keloid in the Japanese population Nat Genetics 42 2010 768 771
11. A.G. Marneros, J.E.C. Norris, S. Watanabe, E. Reichenberger, B.R. Olsen Genome scans provide evidence for keloid susceptibility loci on chromosomes 2q23 and 7p11 J Invest Dermatol 122 2004 1126 1132 (Pubitemid 38651086)
12. J.W. Mall, C. Pollmann, J.M. Müller, R. Büttemeyer Keloid of the earlobe after ear piercing: not only a surgical problem [in German] Chirurg 73 2002 514 516
13. A.S. Vincent, T.T. Phan, A. Mukhopadhyay, H.Y. Lim, B. Halliwell, K.P. Wong Human skin keloid fibroblasts display bioenergetics of cancer cells J Invest Dermatol 128 2007 702 709
14. H. Yoshimoto, H. Ishihara, A. Ohtsuru, K. Akino, R. Murakami, H. Kuroda, H. Namba, M. Ito, T. Fujii, S. Yamashita Overexpression of insulin-like growth factor-1 (IGF-I) receptor and the invasiveness of cultured keloid fibroblasts Am J Pathol 154 1999 883 889 (Pubitemid 29122607)
15. D.Y. Jiang, X.B. Fu, W. Chen, T.Z. Sun [Relationship of overexpression of angiogenesis factors and their receptors with invasive growth of keloid] Chinese Chin J Plast Surg 20 2004 128 131
16. A. Ohtsuru, H. Yoshimoto, H. Ishihara, H. Namba, S. Yamashita Insulin-like growth factor-I (IGF-I)/IGF-I receptor axis and increased invasion activity of fibroblasts in keloid Endocr J 47 Suppl 2000 S41 S44
17. W.S. Wu, F.S. Wang, K.D. Yang, C.C. Huang, Y.R. Kuo Dexamethasone induction of keloid regression through effective suppression of VEGF expression and keloid fibroblast proliferation J Invest Dermatol 126 2006 1264 1271 (Pubitemid 43997906)
18. Y. Wu, Q. Zhang, D.K. Ann, A. Akhondzadeh, H.S. Duong, D.V. Messadi, A.D. Le Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts Am J Physiol Cell Physiol 286 2004 C905 C912
19. F. Syed, A. Bayat Notch signaling pathway in keloid disease: enhanced fibroblast activity in a Jagged-1 peptide dependent manner in lesional versus extra-lesional fibroblasts Wound Repair Regeneration 20 2012 688 706
20. D.E. Boyce, J. Ciampolini, F. Ruge, K.G. Harding, M.M.S.C. Murison Inflammatory cell subpopulations in keloid scars Br J Plast Surg 54 2001 511 516 (Pubitemid 32851238)
21. S.A. Shaker, N.N. Ayuob, N.H. Hajrah Cell talk: a phenomenon observed in the keloid scar by immunohistochemical study Appl Immunohistochem Mol Morphol 19 2011 153
22. I. Bracho-Valdes, P. Moreno-Alvarez, I. Valencia-Martienz, E. Robles-Molina, L. Chavez-Vargas, J. Vazquez-Prado mTORC1 and mTORC2-interacting proteins keep their multifunctional partners focused IUBMB Life 63 2011 896 914
23. D. Benjamin, M. Colombi, C. Moroni, M.N. Hall Rapamycin passes the torch: a new generation of mTOR inhibitors Nat Rev Drug Discovery 10 2011 868 880
24. G.L. Gravina, F. Marampon, F. Petini, L. Biordi, D. Sherris, E.A. Jannini, V. Tombolini, C. Festuccia The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells Endocr Relat Cancer 18 2011 385 400
25. K. Yu, C. Shi, L. Toral-Barza, J. Lucas, B. Shor, J.E. Kim, W.G. Zhang, R. Mahoney, C. Gaydos, L.A. Tardio Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2 Cancer Res 70 2010 621 631
26. C.A. Sparks, D.A. Guertin Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy Oncogene 29 2010 3733 3744
27. Q. Xue, B. Hopkins, C. Perruzzi, D. Udayakumar, D. Sherris, L.E. Benjamin Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability Cancer Res 68 2008 9551 9557
28. C.M. Chresta, B.R. Davies, I. Hickson, T. Harding, S. Cosulich, S.E. Critchlow, J.P. Vincent, R. Ellston, D. Jones, P. Sini AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity Cancer Res 70 2010 288 298
29. J.M. Garcia-Martinez, J. Moran, R.G. Clarke, A. Gray, S.C. Cosulich, C.M. Chresta, D.R. Alessi Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) Biochem J 421 2009 29 42
30. G. Marshall, Z. Howard, J. Dry, S. Fenton, D. Heathcote, N. Gray, H. Keen, A. Logie, S. Holt, P. Smith Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055 Biochem Soc Trans 39 2011 456 459
31. C.T. Ong, Y.T. Khoo, A. Mukhopadhyay, D.V. Do, I.J. Lim, O. Aalami, T.T. Phan mTOR as a potential therapeutic target for treatment of keloids and excessive scars Exp Derm 16 2007 394 404 (Pubitemid 46585367)
32. Q. Zhang, A.P. Kelly, L. Wang, S.W. French, X. Tang, H.S. Duong, D.V. Messadi, A.D. Le Green tea extract and (-)-epigallocatechin-3-gallate inhibit mast cell-stimulated type I collagen expression in keloid fibroblasts via blocking PI-3K/Akt signaling pathways J Invest Dermatol 126 2006 2607 2613 (Pubitemid 44764044)
33. Y.T. Khoo, C.T. Ong, A. Mukhopadhyay, H.C. Han, D.V. Do, I.J. Lim, T.T. Phan Upregulation of secretory connective tissue growth factor (CTGF) in keratinocytes-fibroblast coculture contributes to keloid pathogenesis J Cell Physiol 208 2006 336 343 (Pubitemid 43993424)
34. A. Mukhopadhyay, D.V. Do, C.T. Ong, Y.T. Khoo, J. Masilamani, S.Y. Chan, A.S. Vincent, P.K. Wong, C.P. Lim, X. Cao The role of SCF and c-KIT in keloid pathogenesis: do tyrosine kinase inhibitors have a potential therapeutic role? Br J Dermatol 164 2010 372 386
35. D.V. Do, C.T. Ong, Y.T. Khoo, A. Carbone, C.P. Lim, S. Wang, A. Mukhopadhyay, X. Cao, D.H. Cho, X.Q. Wei Interleukin-18 system plays an important role in keloid pathogenesis via epithelial-mesenchymal interactions Br J Dermatol 166 2012 1275 1288
36. R. Bagabir, F. Syed, R. Paus, A. Bayat Long-term organ culture of keloid disease tissue Exp Dermatol 21 2012 376 381
37. B. Shih, E. Garside, D.A. McGrouther, A. Bayat Molecular dissection of abnormal wound healing processes resulting in keloid disease Wound Repair Regen 18 2010 139 153
38. J.W. Mall, C. Pollmann, J.M. Muller, R. Buttemeyer [Keloid of the earlobe after ear piercing: not only a surgical problem] German Chirurg 73 2002 514 516
39. A. Mukhopadhyay, D.V. Do, C.T. Ong, Y.T. Khoo, J. Masilamani, S.Y. Chan, A.S. Vincent, P.K. Wong, C.P. Lim, X. Cao The role of SCF and c-KIT in keloid pathogenesis: do tyrosine kinase inhibitors have a potential therapeutic role? Br J Dermatol 164 2011 372 386
40. E.T. Anthony, P. Lemonas, H.A. Navsaria, G.C. Moir The cost effectiveness of intralesional steroid therapy for keloids Dermatol Surg 36 2010 1624 1626
41. C. Bermueller, G. Rettinger, T. Keck Auricular keloids: treatment and results Eur Arch Otorhinolaryngol 267 2010 575 580
42. N.P. Patel, A. Lawrence Cervino Keloid treatment: is there a role for acellular human dermis (Alloderm)? J Plast Reconstr Aesthet Surg 63 2010 1344 1348
43. G. Larios, S. Gregoriou, D. Rigopoulos Letter: further options for treatment of hypertrophic scars and keloids Dermatol Surg 36 2010 268 269
44. G. Juckett, H. Hartman-Adams Management of keloids and hypertrophic scars Am Fam Physician 80 2009 253 260
45. D. Shegogue, M. Trojanowska Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway J Biol Chem 279 2004 23166 23175 (Pubitemid 38685622)
46. A.M. Bujor, J. Pannu, S. Bu, E.A. Smith, R.C. Muise-Helmericks, M. Trojanowska Akt blockade downregulates collagen and upregulates MMP1 in human dermal fibroblasts J Invest Dermatol 128 2008 1906 1914 (Pubitemid 352001221)
47. H.W. Liu, B. Cheng, W.L. Yu, R.X. Sun, D. Zeng, J. Wang, Y.X. Liao, X.B. Fu Angiotensin II regulates phosphoinositide 3 kinase/Akt cascade via a negative crosstalk between AT1 and AT2 receptors in skin fibroblasts of human hypertrophic scars Life Sci 79 2006 475 483 (Pubitemid 43884756)
48. W.T. Liao, H.S. Yu, J.L. Arbiser, C.H. Hong, B. Govindarajan, C.Y. Chai, W.J. Shan, Y.F. Lin, G.S. Chen, C.H. Lee Enhanced MCP-1 release by keloid CD14+ cells augments fibroblast proliferation: role of MCP-1 and Akt pathway in keloids Exp Dermatol 19 2010 e142 e150
49. H. Zhou, Y. Luo, S. Huang Updates of mTOR inhibitors Anticancer Agents Med Chem 10 2010 571 581
50. F. Lin, D. Sherris, J.H. Beijnen, O. Van Tellingen High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates J Chromatogr B Analyt Technol Biomed Life Sci 879 2011 3823 3831
51. R. Diaz, P.A. Nguewa, J.A. Diaz-Gonzalez, E. Hamel, O. Gonzalez-Moreno, R. Catena, D. Serrano, M. Redrado, D. Sherris, A. Calvo The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer Br J Cancer 100 2009 932 940
52. T. Xiang, Y. Jia, D. Sherris, S. Li, H. Wang, D. Lu, Q. Yang Targeting the Akt/mTOR pathway in Brca1-deficient cancers Oncogene 30 2011 2443 2450
53. A.C. Hsieh, D. Ruggero Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer Clin Cancer Res 16 2010 4914 4920
54. F. Syed, E. Ahmadi, S.A. Iqbal, S. Singh, D.A. McGrouther, A. Bayat Fibroblasts from the growing margin of keloid scars produce higher levels of collagen I and III compared with intralesional and extralesional sites: clinical implications for lesional site-directed therapy Br J Dermatol 164 2011 83 96
55. F. Syed, A. Thomas, S. Singh, V. Kolluru, S. Emeigh Hart, A. Bayat In vitro study of novel collagenase (Xiaflex) on Dupuytren's disease fibroblasts displays unique drug related properties PloS One 7 2012 e31430
56. J.M. Atienza, J. Zhu, X. Wang, X. Xu, Y. Abassi Dynamic monitoring of cell adhesion and spreading on microelectronic sensor arrays J Biomol Screening 10 2005 795 805 (Pubitemid 41818155)
57. Z. Lu, S. Hasse, E. Bodo, C. Rose, W. Funk, R. Paus Towards the development of a simplified long-term organ culture method for human scalp skin and its appendages under serum-free conditions Exp Dermatol 16 2007 37 44 (Pubitemid 44890349)
58. X.M. Ma, J. Blenis Molecular mechanisms of mTOR-mediated translational control Nat Rev Mol Cell Biol 10 2009 307 318
59. N. Hay, N. Sonenberg Upstream and downstream of mTOR Genes Dev 18 2004 1926 1945 (Pubitemid 39071573)
60. M. Calderon, W.T. Lawrence, A.J. Banes Increased proliferation in keloid fibroblasts wounded in vitro J Surg Res 61 1996 343 347 (Pubitemid 26087681)
61. G. Park, B.S. Yoon, J.H. Moon, B. Kim, E.K. Jun, S. Oh, H. Kim, H.J. Song, J.Y. Noh, C.H. Oh Green tea polyphenol epigallocatechin-3-gallate suppresses collagen production and proliferation in keloid fibroblasts via inhibition of the STAT3-signaling pathway J Invest Dermatol 128 2008 2429 2441
62. A.J. Ridley, M.A. Schwartz, K. Burridge, R.A. Firtel, M.H. Ginsberg, G. Borisy, J.T. Parsons, A.R. Horwitz Cell migration: integrating signals from front to back Science 302 2003 1704 1709 (Pubitemid 37505725)
63. E. Jacinto, R. Loewith, A. Schmidt, S. Lin, M.A. Ruegg, A. Hall, M.N. Hall Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive Nat Cell Biol 6 2004 1122 1128 (Pubitemid 39468014)
64. L. Liu, L. Chen, J. Chung, S. Huang Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins Oncogene 27 2008 4998 5010
65. Y.C. Hsu, M.J. Chen, Y.M. Yu, S.Y. Ko, C.C. Chang Suppression of TGF-β1/SMAD pathway and extracellular matrix production in primary keloid fibroblasts by curcuminoids: its potential therapeutic use in the chemoprevention of keloid Arch Dermatol Res 302 2010 1 8
66. A. Roychowdhury, R. Sharma, S. Kumar Recent advances in the discovery of small molecule mTOR inhibitors Future 2 2010 1577 1589
67. T.L. Yuan, L.C. Cantley PI3K pathway alterations in cancer: variations on a theme Oncogene 27 2008 5497 5510
68. Z.A. Knight, K.M. Shokat Chemically targeting the PI3K family Biochem Soc Trans 35 2007 245 249 (Pubitemid 46596480)
69. S.V. Bhagwat, A.P. Crew Novel inhibitors of mTORC1 and mTORC2 Curr Opin Invest Drugs 11 2010 638 645
70. C.K. Yip, K. Murata, T. Walz, D.M. Sabatini, S.A. Kang Structure of the human mTOR complex I and its implications for rapamycin inhibition Mol Cell 38 2010 768 774
71. J. Bain, L. Plater, M. Elliott, N. Shpiro, C.J. Hastie, H. McLauchlan, I. Klevernic, J.S.C. Arthur, D.R. Alessi, P. Cohen The selectivity of protein kinase inhibitors: a further update Biochem J 408 2007 297 315
72. J. LoPiccolo, G.M. Blumenthal, W.B. Bernstein, P.A. Dennis Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations Drug Resist Updates 11 2008 32 50
73. G.P. Lewis, E.A. Chapin, J. Byun, G. Luna, D. Sherris, S.K. Fisher Muller cell reactivity and photoreceptor cell death are reduced after experimental retinal detachment using an inhibitor of the Akt/mTOR pathway Invest Ophthalmol Vis Sci 50 2009 4429 4435
74. D. Morgensztern, H.L. McLeod PI3K/Akt/mTOR pathway as a target for cancer therapy Anticancer Drugs 16 2005 797 803 (Pubitemid 41215743)
75. M. Jinnin, H. Ihn, K. Yamane, K. Tamaki Interleukin-13 stimulates the transcription of the human alpha 2 (I) collagen gene in human dermal fibroblasts J Biol Chem 279 2004 41783 41791 (Pubitemid 39313625)
76. Y. Asano, H. Ihn, K. Yamane, M. Jinnin, Y. Mimura, K. Tamaki Phosphatidylinositol 3-kinase is involved in alpha 2(I) collagen gene expression in normal and scleroderma fibroblasts Journal Immunol 172 2004 7123 7135 (Pubitemid 38669156)
77. G. Svegliati Baroni, F. Ridolfi, A. Di Sario, S. Saccomanno, E. Bendia, A. Benedetti, P. Greenwel Intracellular signaling pathways involved in acetaldehyde-induced collagen and fibronectin gene expression in human hepatic stellate cells Hepatology 33 2001 1130 1140 (Pubitemid 32378212)
78. E.S. White, R.L. Sagana, A.J. Booth, M. Yan, A.M. Cornett, C.A. Bloomheart, J.L. Tsui, C.A. Wilke, B.B. Moore, J.D. Ritzenthaler Control of fibroblast fibronectin expression and alternative splicing via the PI3K/Akt/mTOR pathway Exp Cell Res 316 2010 2644 2653
79. N. Lloberas, J.M. Cruzado, M. Franquesa, I. Herrero-Fresneda, J. Torras, G. Alperovich, I. Rama, A. Vidal, J.M. Grinyó Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats J Am Soc Nephrol 17 2006 1395 1404 (Pubitemid 43673420)
80. E. Biecker, A. De Gottardi, M. Neef, M. Unternahrer, V. Schneider, M. Ledermann, H. Sagesser, S. Shaw, J. Reichen Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms J Pharmacol Exp Ther 313 2005 952 961 (Pubitemid 40726999)
81. J.L. Jacot, D. Sherris Potential therapeutic roles for inhibition of the PI3K/Akt/mTOR pathway in the pathophysiology of diabetic retinopathy J Ophthalmol 2011 2011 589813